In this issue:
Psoriasis risk in atopic dermatitis treated with dupilumab
Bimekizumab over 4 years in moderate-to-severe plaque psoriasis
Vitamin D levels and risks of mortality and CVD in psoriasis
Cardiovascular safety of systemic psoriasis treatments
Predictors of early response to vunakizumab
Real-world skin clearance and QoL with risankizumab
Cardiovascular and kidney outcomes after systemic plaque psoriasis treatment
Time to onset of action for biologics and targeted treatments
Safety of guselkumab in patients with comorbidities
Prescribing in psoriasis with concomitant malignancy
Improving cardiovascular outcomes in the psoriasis cohort
Please login below to download this issue (PDF)